ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3037% below fair value
$13.24+0.05 (+0.38%)
Close on Nov 12, 2026Market cap $2.97BP/E 17.2Yield –
ADMA Biologics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ADMA Biologics's ebitda for the twelve months ending Sep 30, 2026 was $248.43M, up 42.0% year over year. For fiscal 2025 it was $199.44M, up 36.0% from the year before. The highest annual figure on record is $199.44M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.44M | +36.0% |
| FY2024 | Dec 31, 2024 | $146.68M | +401.8% |
| FY2023 | Dec 31, 2023 | $29.23M | – |
| FY2022 | Dec 31, 2022 | -$32.97M | – |
| FY2021 | Dec 31, 2021 | -$53.57M | – |
| FY2020 | Dec 31, 2020 | -$61.71M | – |
| FY2019 | Dec 31, 2019 | -$39.02M | – |
| FY2018 | Dec 31, 2018 | -$57.69M | – |
| FY2017 | Dec 31, 2017 | -$37.81M | – |
| FY2016 | Dec 31, 2016 | -$16.93M | – |
| FY2015 | Dec 31, 2015 | -$15.04M | – |
| FY2014 | Dec 31, 2014 | -$15.77M | – |
| FY2013 | Dec 31, 2013 | -$14.83M | – |
| FY2012 | Dec 31, 2012 | -$7.73M | – |
| FY2011 | Dec 31, 2011 | -$4.40M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $69.46M | +31.0% |
| Q2 FY2026 | Jun 30, 2026 | $54.15M | +20.9% |
| Q1 FY2026 | Mar 31, 2026 | $60.07M | +63.3% |
| Q4 FY2025 | Dec 31, 2025 | $64.75M | +60.6% |
| Q3 FY2025 | Sep 30, 2025 | $53.01M | +27.6% |
| Q2 FY2025 | Jun 30, 2025 | $44.80M | +9.0% |
| Q1 FY2025 | Mar 31, 2025 | $36.78M | +55.1% |
| Q4 FY2024 | Dec 31, 2024 | $40.32M | +149.9% |
| Q3 FY2024 | Sep 30, 2024 | $41.54M | +292.4% |
| Q2 FY2024 | Jun 30, 2024 | $41.10M | +2780.2% |
| Q1 FY2024 | Mar 31, 2024 | $23.72M | +2082.2% |
| Q4 FY2023 | Dec 31, 2023 | $16.13M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.59M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.43M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.90M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.17M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.53M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.47M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.94M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.27M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.12M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.82M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.90M | – |
See a number that looks wrong?